Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 4 de 4
Int J Immunopathol Pharmacol ; 35: 20587384211059675, 2021.
Article in English | MEDLINE | ID: covidwho-1582485


INTRODUCTION: The fully-human monoclonal anti-interleukin (IL)-1ß antibody canakinumab may inhibit the production of inflammatory mediators in patients with coronavirus disease 2019 (COVID-19) and the hyperinflammatory response potentially leading to acute respiratory distress syndrome. OBJECTIVES: The goal of our retrospective, observational analysis was to evaluate the safety and efficacy of subcutaneous (s.c.) canakinumab in combination with our standard of care (SOC) treatment of selected patients with COVID-19 with respiratory failure and elevated reactive pro-inflammatory markers. METHODS: Eight participants received two doses of s.c. canakinumab 150 mg (or 2 mg/kg for participants weighing ≤40 kg) in addition to SOC. 12 patients received only SOC treatment. RESULTS: Canakinumab treatment reduced the need for mechanical ventilation and reduced proinflammatory markers, resulting in an amelioration of the final outcome, with respect to the control group who received SOC alone. The treatment was safe and well tolerated; no adverse events were reported. CONCLUSION: The use of canakinumab (300 mg, s.c.) in the early stage of COVID-19 with mild-to-moderate respiratory failure was superior to SOC at preventing clinical deterioration and may warrant further investigation as a treatment option for patients with COVID-19 who experience a hyperinflammatory response in the early stage of the disease.

Antibodies, Monoclonal, Humanized , COVID-19 , Interleukin-1beta , Respiration, Artificial , Antibodies, Monoclonal, Humanized/administration & dosage , Antibodies, Monoclonal, Humanized/adverse effects , Antibodies, Monoclonal, Humanized/immunology , Biomarkers/blood , COVID-19/complications , COVID-19/epidemiology , COVID-19/immunology , COVID-19/therapy , Dose-Response Relationship, Drug , Female , Humans , Inflammation Mediators/blood , Interleukin-1beta/antagonists & inhibitors , Interleukin-1beta/immunology , Italy/epidemiology , Male , Middle Aged , Monitoring, Immunologic/methods , Outcome and Process Assessment, Health Care , Patient Selection , Respiration, Artificial/methods , Respiration, Artificial/statistics & numerical data , Retrospective Studies , SARS-CoV-2 , Time-to-Treatment
Future of Food: Journal on Food, Agriculture and Society ; 8(2):1-2, 2020.
Article | WHO COVID | ID: covidwho-739570


How will the COVID-19 pandemic impact food se-curity and virtual water “trade”? This is not an easy question as we must consider the multifaceted and complex nature of the aspects and variables at play. Aspects to consider are both the global food supply system and access to food. The global food system is based on food production, food processing, food transport and trade. Furthermore, elements which could be affected by the virus are the food retailing sector and the income of final consumers. It is also necessary to look at how the pandemic impacts peo-ple’s access to food in rich and poor economies, in rural and urban settings. The question therefore is, how is the pandemic impacting all these different as-pects? Current studies have connected how the cur-rent food-system plays a determinant role in the use of irrigation water worldwide (1). When food is trad-ed, the consequent “trade” of water embedded in food – virtual water “trade”- happens in parallel (1). Thus, if any disruption or greater change is going to happen in the current food-trade and food patterns, a parallel change in global virtual water trade is likely to follow.